Alpha memo: glynac glycine acetylcysteine improves translation boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rewrite the one-sentence alpha so it states a single bounded signal (e.g., 'GlyNAC shows concordant glutathione/oxidative-stress/cognition improvements in old mice and in a small human pilot, but human evidence is limited to one open-label pilot from the originating lab').
2. Justify or drop the 'translation_boundary' framing: either articulate the specific mouse↔human divergence (endpoint, population, effect size) that constitutes the boundary, or rename the memo to reflect concordance rather than boundary.
3. Truncate Receipt 1 title cleanly and align title/anchor construct to GlyNAC in both receipts.
4. Add explicit limitations: n size of human pilot, open-label design, single-site/single-investigator, short duration (24 weeks), no hard clinical endpoints (dementia incidence).
5. Specify actionable gaps: need for independent replication, RCT with cognitive endpoints, dose-finding, comparison to NAC or glycine alone.

Major issues

• The 'alpha' is malformed: it concatenates two paper titles verbatim with bridging text ('He made us expect...forces the update...') rather than stating a clear research signal.
• The title claims a 'translation boundary' but the two receipts are from the same investigator group (Sekhar RV) and are broadly concordant (mouse brain improvements + human pilot improvements), so the 'boundary/surprising reversal' framing is not supported by the evidence pair.
• No explicit methodological or endpoint-level contrast is drawn between the mouse and human receipts — the claim that human evidence is 'bounded by population or endpoint' is asserted, not demonstrated.

Minor issues

• Receipt 1 title is truncated ('...Brain He') and should be cleaned to 'Brain Health'.
• Caveats/falsifiers are generic and do not name specific measurable falsifiers relevant to GlyNAC (e.g., replication by an independent group, dose-response, hard clinical endpoints).
• Search receipt metadata (hits=10, shards=1525/1525, papers_searched=1456919317) is not contextualized and reads as noise.
• No next-step gaps are articulated (RCT design, independent replication, cognitive endpoint durability, comparator vs. NAC alone).

Reviewer note

The memo identifies a real evidence pair (Sekhar-lab mouse brain study, 2023; Sekhar-lab human pilot, 2021) and the source bundle is internally consistent with the cited findings. However, the central claim of a 'translation boundary' or 'surprising' update is not substantiated: both receipts originate from the same group and report concordant improvements. The alpha sentence is a literal concatenation of two titles with bridging text, not a coherent research signal. The claim that human evidence is 'bounded by population or endpoint' is asserted without specifying which population or endpoint. Source grounding is acceptable (two real primary sources, correctly cited by DOI and year). Synthesis is weak: no integration of effect direction, no discussion of concordance vs. divergence, no articulation of what would falsify the signal. A revise is warranted because the bundle is sound and the topic is legitimate, but the framing and synthesis need bounded fixes before the memo can stand as a clear, source-grounded signal.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis